This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and ...

3.2 Asthma treatment in clinical practice follows the NICE guideline on asthma and the Global Initiative for Asthma (GINA) guideline (which includes the use of biological treatments). If asthma ...

Transferring people aged 12 and over from pathways previously recommended by NICE 1.7.7 Change treatment for people with confirmed asthma who are currently using a short-acting beta 2 agonist (SABA) ...

Transferring from other treatment pathways. 1.7.8 Consider changing treatment for people with confirmed asthma who are currently using a short-acting beta2 agonist (SABA) only to a low-dose ...

London, UK, Tuesday 28 March 2023 – AstraZeneca today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Tezspire (tezepelumab) ...

Biochemical Society. (2017, October 12). Possible new treatment pathway for severe allergic asthma. ScienceDaily. Retrieved May 3, 2025 from www.sciencedaily.com / releases / 2017 / 10 ...

Nice recommended the use of the treatment – also known as Tezspire and made by pharmaceutical firm AstraZeneca – as an “additional maintenance treatment” for people over 12 with severe asthma.

“The asthma service has worked hard with hospital staff to improve the whole pathway and, thanks to this, the number of patients receiving a care bundle has increased,” she said. “There are also ...

A team has transformed care so asthma patients get treatment more quickly and closer to home, with plans for a regional hub. Find out more. LOGIN / FREE TRIAL Menu Menu . ... Nurse-led treatment ...